Futures Forum: Brexit: and 'Can we have our £350m for the NHS, please?'
Futures Forum: Brexit: and post truth politics: no extra money for the NHS
Futures Forum: Brexit: and "a bonus for the NHS"
Futures Forum: Brexit: and the future of healthcare
Futures Forum: Brexit: and £350million for Devon's hospitals
Parliament's health select committee has been looking into things a little:
Committee seeks clarity on transition deal for medicines - News from Parliament - UK Parliament
As has the pharmaceutical industry:
Health Select Committee warns of Brexit risks to new drugs and patient safety
The Pharmaceutical Journal
21 MAR 2018
By Debbie Andalo
MPs have warned that abandoning regulatory alignment with the EMA following Brexit could have a major negative impact on the quality of healthcare in the UK.
Maintaining regulatory alignment with the European Medicines Agency is critical to maintaining quality of care in the UK, following Brexit, MPs have warned
Patient access to new drugs, patient safety and future investment in the life science industry are all at risk if the UK fails to maintain regulatory alignment with the European Medicines Agency (EMA) after Brexit, MPs have warned.
MPs on the House of Commons Health Select Committee (HSC) also want the UK to retain membership — or at least be an observer on the EMA’s Pharmacovigilance Risk Assessment Committee — after leaving the European Union (EU), and keep its membership of EMA drugs databases.
The government, as a priority, should additionally ensure that there is “mutual recognition” of pharmacovigilance studies by EMA and the UK’s Medicines and Healthcare products Regulatory Agency, the committee said in its report ‘Brexit: medicines, medical devices and substances of human origin’.
The report said: “Failure to gain access to EU pharmacovigilance systems would have serious consequences for UK medicine and drug safety.
“It would not be possible, let alone desirable, to draw up a UK standalone system by the time the UK exits the EU. Contingency planning in this area would highlight the risks of failure to access EU pharmacovigilance systems and needs to prompt urgent action.”
Health Select Committee warns of Brexit risks to new drugs and patient safety | News | Pharmaceutical Journal
Here in a video uploaded earlier today is the Exeter MP Ben Bradshaw, member of the committee, giving a summary of their views:
Ben Bradshaw MP: "Our health service face one of the most significant impacts from Brexit" - YouTube
MPs have warned that abandoning regulatory alignment with the EMA following Brexit could have a major negative impact on the quality of healthcare in the UK.
Maintaining regulatory alignment with the European Medicines Agency is critical to maintaining quality of care in the UK, following Brexit, MPs have warned
Patient access to new drugs, patient safety and future investment in the life science industry are all at risk if the UK fails to maintain regulatory alignment with the European Medicines Agency (EMA) after Brexit, MPs have warned.
MPs on the House of Commons Health Select Committee (HSC) also want the UK to retain membership — or at least be an observer on the EMA’s Pharmacovigilance Risk Assessment Committee — after leaving the European Union (EU), and keep its membership of EMA drugs databases.
The government, as a priority, should additionally ensure that there is “mutual recognition” of pharmacovigilance studies by EMA and the UK’s Medicines and Healthcare products Regulatory Agency, the committee said in its report ‘Brexit: medicines, medical devices and substances of human origin’.
The report said: “Failure to gain access to EU pharmacovigilance systems would have serious consequences for UK medicine and drug safety.
“It would not be possible, let alone desirable, to draw up a UK standalone system by the time the UK exits the EU. Contingency planning in this area would highlight the risks of failure to access EU pharmacovigilance systems and needs to prompt urgent action.”
Health Select Committee warns of Brexit risks to new drugs and patient safety | News | Pharmaceutical Journal
Here in a video uploaded earlier today is the Exeter MP Ben Bradshaw, member of the committee, giving a summary of their views:
Ben Bradshaw MP: "Our health service face one of the most significant impacts from Brexit" - YouTube
.
.
.
.
.
No comments:
Post a Comment